Migraine affects approximately one billion people worldwide and is the second leading cause of years lived with disability globally. Calcitonin gene-related peptide pathway therapies, including gepants and anti-CGRP monoclonal antibodies, have transformed both acute and preventive treatment options. Personalised treatment selection based on attack frequency, disability, and comorbidities guides modern migraine management.
Migraine Linked to Increased Vascular Dementia Odds in Observational Data
Observational studies indicate a consistent association between a history of migraine and elevated odds for developing vascular dementia later in life.
GLP-1s do not improve migraines, but reduce healthcare utilisation
GLP-1 receptor agonists do not reduce migraine days, but are associated with decreased healthcare utilisation for migraine.
CGRP Monoclonal Antibodies for Migraine Linked to Fracture Risk
New data indicate CGRP monoclonal antibodies, used for migraine prevention, may be associated with an increased risk of bone fractures. Clinicians should consider this risk.
CGRP Inhibitors for Migraine: CV Safety Data Limited in High-Risk Patients
CGRP-targeted therapies are effective for migraine prevention, but cardiovascular safety data is limited in patients with established vascular disease.